Breaking News Instant updates and real-time market news.

STML

Stemline

$10.33

0.5 (5.09%)

, PFE

Pfizer

$38.29

0.26 (0.68%)

18:33
12/06/19
12/06
18:33
12/06/19
18:33

Stemline names Robert Francomano as Chief Commercial Officer

Most recently, Francomano served as Senior Vice President, Global Head of Commercial and Medical Affairs for Stemline (STML). Prior to this, Francomano garnered extensive oncology experience operating in global roles for Baxalta, Pfizer (PFE) and GlaxoSmithKline (GSK), where he developed strategies for assets in clinical development from Phase I through Phase IV.

STML

Stemline

$10.33

0.5 (5.09%)

PFE

Pfizer

$38.29

0.26 (0.68%)

GSK

GlaxoSmithKline

$45.51

0.29 (0.64%)

  • 07

    Dec

  • 09

    Dec

  • 11

    Dec

STML Stemline
$10.33

0.5 (5.09%)

06/20/19
JPMS
06/20/19
NO CHANGE
JPMS
Overweight
Data suggests Q2 Elzonris sales beat for Stemline, says JPMorgan
JPMorgan analyst Jessica Fye views the latest Symphony health monthly institutional data as encouraging for Stemline Therapeutics' Q2 Elzonris sales. The data is suggestive of a beat versus the consensus Q2 revenue estimate of $7M, Fye tells investors in a research note. The analyst sees a positive risk/reward in the stock with potential for label expansion or higher than expected patient numbers to drive upside over time. She reiterates an Overweight rating on Stemline Therapeutics
08/02/19
WEDB
08/02/19
UPGRADE
WEDB
Outperform
Stemline upgraded to Outperform from Neutral at Wedbush
08/02/19
WEDB
08/02/19
UPGRADE
Target $20
WEDB
Outperform
Wedbush upgrades Stemline to Outperform after Elzonris sales beat
Wedbush analyst David Nierengarten upgraded Stemline Therapeutics to Outperform from Neutral and raised his price target for the shares to $20 from $18. The stock in afternoon trading is up 16%, or $2.12, to $15.15 following this morning's Q2 results. Stemline's risk/reward is more favorable at current levels after Elzonris topped expectations in the quarter, Nierengarten tells investors in a research note.
08/06/19
PIPR
08/06/19
NO CHANGE
Target $25
PIPR
Overweight
NTAP suggests 'significant upside' to Stemline model assumptions, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro notes that Stemline was granted approval for a new technology add-on payment for Elzonris, which allows for additional reimbursement for Medicare patients beyond the DRG-based payment. While notable, within the CMS decision is further detail around Elzonris dosing that could have "significant positive" implications to his model assumptions. Mainly, the analyst may be under-modeling the number of vials per dose and pricing per newly diagnosed patient may be 90% more than he was modeling. Catanzaro reiterates an Overweight rating and $25 price target on the shares.
PFE Pfizer
$38.29

0.26 (0.68%)

11/25/19
PIPR
11/25/19
INITIATION
Target $2.5
PIPR
Overweight
Opko Health initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff initiated coverage of Opko Health (OPK) with an Overweight rating and $2.50 price target. The company's partner Pfizer (PFE) recently reported positive Phase III data on once-weekly somatrogo in pediatric growth hormone deficiency, Tenthoff tells investors in a research note. The analyst is confident in the drug and notes that Opko is eligible for up to $275M in milestones plus gross profit share on Genotropin and somatrogon revenue.
11/12/19
PIPR
11/12/19
NO CHANGE
Target $185
PIPR
Overweight
Time to dismiss Solid Biosciences as Sarepta competitor, says Piper Jaffray
Piper Jaffray analyst Danielle Brill says that while she had dismissed Solid Biosciences' (SLDB) microdystophin gene therapy program as a competitive threat to Sarepta Therapeutics (SRPT), some investors worried that Solid could provide compelling data after adjusting protocol and moving up the dose. However, today's report of another clinical hold confirms that Solid's construct is toxic, indicating that Pfizer's (PFE) may to too, Brill tells investors in a research note. The analyst points out that both Solid and Pfizer use AAV9 and have had complement mediated serious adverse events after dosing just a few patients. Solid's program reaffirms her view that Sarepta's safety profile is differentiated. It is unlikely that the competition "is viable, let alone will ever catch up," says Brill. She keeps an Overweight rating on Sarepta Therapeutics with a $185 price target. The stock in midday trading is up 4% to $99.02 while Solid Biosciences is down 71% to $3.22.
11/06/19
PIPR
11/06/19
NO CHANGE
Target $70
PIPR
Neutral
Ionis Pharmaceuticals price target lowered to $70 from $75 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren lowered his price target on Ionis Pharmaceuticals (IONS) to $70 and kept his Neutral rating after its Q3 results, saying that while the quarter was "strong" thanks to the recent $250M upfront payment from Pfizer (PFE), results for its Tegsedi were "uninspiring". The analyst states that an acceleration in Tegsedi is needed soon for him to become more positive on the name ahead of the "potential Phase I/II OLE +natural history Huntington's study readouts next year."
11/01/19
RAJA
11/01/19
UPGRADE
Target $24
RAJA
Outperform
Intellia Therapeutics upgraded to Outperform at Raymond James
Raymond James analyst Steven Seedhouse upgraded Intellia Therapeutics to Outperform from Market Perform with a $24 price target. In a research note to investors, Seedhouse says Intellia's NTLA-2001 is poised to benefit from the "heavy lifting" Pfizer (PFE) is doing commercially with Vyndaqel in ATTR-cardiomyopathy, adding that Intellia is also advancing manufacturing related activities in support of a Phase 1 trial for engineered cell program WT1-TCR in AML. The analyst also says Intellia's lead gene editing program, NTLA-2001 has "really good" primate data showing TTR knockdown potentially better than Alnylam's (ALNY) patisiran. He expects the market will already start to impute downstream clinical benefit for NTLA-2001 after only a few patients with initial TTR knockdown data, because of the collective data for Ionis Pharmaceuticals' (IONS) inotersen and Alnylam's patisiran showing knockdown is relevant.
GSK GlaxoSmithKline
$45.51

0.29 (0.64%)

11/21/19
UBSW
11/21/19
UPGRADE
UBSW
Buy
GlaxoSmithKline upgraded to Buy from Neutral at UBS
UBS upgraded GlaxoSmithKline to Buy from Neutral with a price target of 1900 pence, up from 1610 pence.
11/21/19
11/21/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lowe's (LOW) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Kate McShane saying the retailer's Q3 results represented a positive step in rebuilding investor confidence around its execution capabilities and transformation strategy. 2. NorthWestern (NWE) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jonathan Reeder saying the stock's price-to-earnings "looks too steep" at current valuation levels. 3. GlaxoSmithKline (GSK) upgraded to Buy from Neutral at UBS. 4. Kimco Realty (KIM) upgraded to Outperform from Sector Perform at Scotiabank. 5. Kulicke & Soffa (KLIC) upgraded to Buy from Neutral at DA Davidson analyst Thomas Diffely saying the company is now past its "trough quarter" and expects its "upcoming cyclical drivers" to generate revenue growth as "pockets of strength in the wirebonding market" serve as initial indicators of a broader industry recovery. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/02/19
LEER
12/02/19
INITIATION
Target $53
LEER
Outperform
GlaxoSmithKline initiated with an Outperform at SVB Leerink
SVB Leerink analyst Geoffrey Porges initiated coverage of GlaxoSmithKline with an Outperform rating and $53 price target.
12/03/19
MSCO
12/03/19
NO CHANGE
Target $100
MSCO
Equal Weight
Morgan Stanley sees high odds of Bluebird trading up after multiple myeloma data
Morgan Stanley analyst Matthew Harrison said he sees a high probability, or 75% odds, that Bluebird Bio (BLUE) shares will trade higher following the report of topline results from its KarMMa study of bb2121 as a fourth line or later therapy for the treatment of relapsed/refractory multiple myeloma, which are due by year-end. He said investors are focused on the median progression free survival delivered by the therapy as a gauge of its commercial viability versus other anti-BCMA CAR-T therapies in development at GlaxoSmithKline (GSK) and Bristol-Myers (BMY) in partnership with Regeneron (REGN). In a scenario where median PFS is greater than or equal to 11.5 months and overall response rate is greater than or equal to 85%, Harrison sees Bluebird shares having 20%-30% or more upside. If the median PFS is equal to or less than 9 months and ORR is below 80%, he thinks bb2121 would likely still be approvable, but sees shares down 10%-20%. In what he views as the most likely scenario - with mPFS of about 10 months and ORR of about 80% - Harrison sees 10%-20% upside in Bluebird shares. He keeps an Equal Weight rating and $100 price target on the stock.

TODAY'S FREE FLY STORIES

03:30
01/20/20
01/20
03:30
01/20/20
03:30
General news
FX Action: USD-CAD ebbed fractionally lower »

FX Action: USD-CAD ebbed…

03:05
01/20/20
01/20
03:05
01/20/20
03:05
General news
Asian Market Update: »

Asian Market Update:…

03:05
01/20/20
01/20
03:05
01/20/20
03:05
General news
FX Update: The dollar has seen modest weakness »

FX Update: The dollar has…

FB

Facebook

$222.01

0.23 (0.10%)

16:50
01/19/20
01/19
16:50
01/19/20
16:50
Periodicals
Facebook blames technical error for vulgar translation, Reuters reports »

Facebook blamed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

, SPX

S&P 500

$0.00

(0.00%)

16:43
01/19/20
01/19
16:43
01/19/20
16:43
Periodicals
China to increase U.S. imports according to 'market principles,' Reuters reports »

China will negotiate with…

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$510.34

-3.065 (-0.60%)

16:33
01/19/20
01/19
16:33
01/19/20
16:33
Periodicals
Tesla closer to opening first European factory with property deal, Reuters says »

Tesla has agreed to buy a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 24

    Feb

  • 23

    Mar

  • 23

    Mar

JPM

JPMorgan

$138.15

0.89 (0.65%)

, BNPQY

BNP Paribas

$0.00

(0.00%)

16:28
01/19/20
01/19
16:28
01/19/20
16:28
Periodicals
JPMorgan to acquire former BNP building in Paris, Bloomberg reports »

JPMorgan (JPM) is buying…

JPM

JPMorgan

$138.15

0.89 (0.65%)

BNPQY

BNP Paribas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

  • 25

    Feb

  • 14

    Apr

BAC

Bank of America

$34.70

-0.03 (-0.09%)

16:25
01/19/20
01/19
16:25
01/19/20
16:25
Periodicals
CEO tells FT Bank of America aims to 'double' slice of U.S. retail business »

Bank of America can…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 15

    Apr

CEL

Cellcom Israel

$3.18

(0.00%)

16:16
01/19/20
01/19
16:16
01/19/20
16:16
Hot Stocks
Cellcom Israel announces CTO resignation »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRCA

Verrica Pharmaceuticals

$15.94

0.21 (1.34%)

16:12
01/19/20
01/19
16:12
01/19/20
16:12
Hot Stocks
Verrica announces presentation of data from Phase 3 CAMP trials of VP-102 »

Verrica Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

SO

Southern Company

$67.25

1.08 (1.63%)

, XEL

Xcel Energy

$65.38

0.34 (0.52%)

16:08
01/19/20
01/19
16:08
01/19/20
16:08
Hot Stocks
Southern Power closes sale of Mankato Energy Center to Xcel Energy »

Southern Power, a…

SO

Southern Company

$67.25

1.08 (1.63%)

XEL

Xcel Energy

$65.38

0.34 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

LIZI

Lizhi

$11.72

(0.00%)

, DNK

Phoenix Tree

$13.50

(0.00%)

09:10
01/19/20
01/19
09:10
01/19/20
09:10
On The Fly
Opening Day: China's Lizhi, Phoenix Tree flat in trading debut »

Lizhi (LIZI), one of…

LIZI

Lizhi

$11.72

(0.00%)

DNK

Phoenix Tree

$13.50

(0.00%)

VEL

Velocity Financial

$13.58

(0.00%)

IMAB

I-MAB

$12.90

(0.00%)

BSBK

Bogota Financial

$11.70

0.195 (1.70%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.